Antibody-Lipid Nanoparticle (LNP) Development Solutions

Creative Biolabs is here to provide you with comprehensive antibody-lipid nanoparticle (LNP) services from design to verification. Our innovative approach offers numerous advantages over traditional drug delivery methods, including improved therapeutic efficacy, reduced off-target effects, and enhanced cellular uptake.

Platform

LNPs can help drugs pass through cell membranes in the body, improving drug stability and bioavailability, as well as reducing drug toxicity.

Nowadays, Creative Biolabs has developed an antibody-LNP technology platform for providing a comprehensive solution for antibody-LNP development, production, validation, and evaluation. Normally, Our platform involves the combination of specific antibodies with lipid-based carriers for delivering nucleic acid drugs or other bioactive molecules. Till now, our antibody-LNP technology has been extensively utilized in multiple biomedical applications, such as for delivering RNA interference (RNAi) therapies and gene editing.

Fig.1 A mRNA-LNP System Has Been Designed to Measure Cytosolic Delivery.^1,3

Services

From designing customized antibodies to formulating optimized LNPs, Creative Biolabs has the knowledge and experience to take your project from concept to completion. In addition to our technical expertise, our specificity is unparalleled. We can design antibodies that specifically target disease-causing molecules, leading to highly effective therapies with minimal side effects. The following is our service process:

STEP 1: Antibody targeting specific antigen is conjugated to liposomal nucleic acid (LNP) for targeted delivery to specific cells or tissues.

STEP 2: LNP-encapsulated nucleic acid is loaded with the genetic material (such as siRNA or mRNA) of interest for gene silencing or expression modulation.

STEP 3: The antibody-LNP complex is injected into the body where the antibody facilitates targeted delivery to the desired cells or tissues.

STEP 4: Once inside the target cells, the genetic material carried by the LNP is released and can exert its therapeutic effects, such as silencing a disease-causing gene or expressing a therapeutic protein.

STEP 5: The combination of antibody targeting and liposomal delivery enhances the specificity, efficacy, and safety of the nucleic acid therapy.

Fig.2 The Specific Killing Analysis of EpCAM-CD3 hFc mRNA-LNP Antibodies.^2,3

Advantages

Creative Biolabs offers top-notch antibody-LNP services with high professionalism, accurate data, and exceptional cost performance. From the initial design phase to the final verification, we work tirelessly to ensure that all aspects of your project are completed with precision and accuracy.

• Enhanced delivery: The use of liposomal nanoparticles allows us for more efficient delivery of nucleic acid molecules, increasing their stability and potential efficacy.
• Reduced off-target effects: By specifically targeting the delivery of nucleic acids to the desired cells with the help of antibodies, the risk of off-target effects is minimized.
• Increased specificity: The use of antibodies enables the targeted delivery of nucleic acids to specific cell types, enhancing the therapeutic potential of the treatment.
• Improved potency: The combination of antibodies and liposomal nanoparticles can enhance the potency of nucleic acid therapies, leading to more effective treatment outcomes.
• Reduced immune response: By specifically targeting the delivery of nucleic acids to specific cells, the risk of triggering an immune response is reduced, improving the overall safety profile of the treatment.

Creative Biolabs has the knowledge and expertise to handle even the most antibody-LNP challenging projects, and we guarantee that our services will exceed your expectations. Contact us now to discover how we can assist you in reaching your objectives. Your satisfaction is our top priority, and we look forward to working with you to bring your project to fruition.

References

1. Liu, Haiyin, et al. "Beyond the Endosomal Bottleneck: Understanding the Efficiency of mRNA/LNP Delivery." Advanced Functional Materials (2024): 2404510.
2. Golubovskaya, Vita, et al. "mRNA-lipid nanoparticle (LNP) delivery of humanized EpCAM-CD3 bispecific antibody significantly blocks colorectal cancer tumor growth." Cancers 15.10 (2023): 2860.
3. under Open Access License CC BY 4.0, without modification.

For research use only. Not intended for any clinical use.